English
Home > Products > Rilmenidine phosphate

China Rilmenidine phosphate Factory

Bear "Customer very first, Quality first" in mind, we work closely with our customers and supply them with efficient and professional services for Rilmenidine phosphate,CAS NO 85409-38-7,85409-38-7,Rilmenidine phosphate API, We have been self-assured to make excellent achievements within the future. We've been looking forward to becoming one within your most trusted suppliers.
Rilmenidine phosphate, We warmly welcome your patronage and will serve our clients both at home and abroad with items of superior quality and excellent service geared to the trend of further development as always. We believe you will benefit from our professionalism soon.

Related Products

Hot Products

  • Related Blog
  • Reviews

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • CAS 148553-50-8 What is Pregabalin?

    Pregabalin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses within the brain that cause seizures. Pregabalin also affects chemicals within the brain that send pain signals across the systema nervosum.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

Related Search

Rilmenidine phosphate API

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept